VIVITRA 440MG INJECTION

VIVITRA 440MG Injection contains trastuzumab, a targeted monoclonal antibody therapy used in the treatment of HER2-positive breast and gastric cancers. It works by specifically binding to HER2 receptors on cancer cells, slowing their growth, and supporting improved treatment outcomes. This injection is administered under the supervision of a qualified oncologist as part of a comprehensive cancer treatment plan.

VIVITRA 440MG Injection is recommended for patients diagnosed with HER2-positive metastatic or early breast cancer and certain gastric cancers, either alone or in combination with chemotherapy. It helps control tumor progression and enhances the effectiveness of other anticancer medicines. Proper medical monitoring is essential to manage dosage, infusion reactions, and treatment response with this advanced pharmaceutical therapy.

VIVITRA 440MG Injection is among the reliable oncology products trusted by healthcare professionals for targeted cancer care. It is developed with strict quality standards to ensure safety, purity, and therapeutic consistency. Choosing quality-assured pharmaceutical solutions like VIVITRA supports better clinical outcomes and dependable oncology treatment management.

Product Features

• Contains trastuzumab 440 mg targeted monoclonal antibody
• Used for HER2-positive breast and gastric cancer treatment
• Administered under medical supervision for safety
• Supports combination therapy with chemotherapy
• High-quality pharmaceutical oncology formulation

How It Helps

• Targets HER2 receptors to slow cancer cell growth
• Improves the effectiveness of chemotherapy treatment
• Helps control tumor progression
• Supports better survival and treatment outcomes